Biogen Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Biogen kazanç ve gelirin sırasıyla yıllık 12.4% ve 1.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

12.4%

Kazanç büyüme oranı

14.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	1.3%
Gelecekteki özkaynak getirisi	13.1%
Analist kapsamı	Good
Son güncelleme	25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

XTRA:IDP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	9,690	2,403	2,574	2,999	27
12/31/2025	9,526	2,132	2,402	2,789	33
12/31/2024	9,641	1,791	2,082	2,499	33
9/30/2024	9,608	1,615	1,768	2,127	N/A
6/30/2024	9,672	1,159	1,571	1,784	N/A
3/31/2024	9,663	1,167	1,284	1,645	N/A
12/31/2023	9,836	1,161	1,236	1,547	N/A
9/30/2023	9,993	1,462	1,026	1,360	N/A
6/30/2023	9,972	2,665	1,123	1,428	N/A
3/31/2023	10,105	3,131	1,421	1,678	N/A
12/31/2022	10,173	3,047	1,141	1,384	N/A
9/30/2022	10,363	2,865	2,173	2,398	N/A
6/30/2022	10,634	2,059	2,315	2,542	N/A
3/31/2022	10,820	1,450	2,773	3,033	N/A
12/31/2021	10,982	1,556	3,345	3,640	N/A
9/30/2021	11,101	1,546	2,107	2,435	N/A
6/30/2021	11,698	1,918	2,461	2,810	N/A
3/31/2021	12,604	3,012	3,149	3,532	N/A
12/31/2020	13,445	4,001	3,678	4,230	N/A
9/30/2020	14,263	5,082	5,841	6,557	N/A
6/30/2020	14,487	5,927	6,349	7,071	N/A
3/31/2020	14,422	5,879	6,282	7,086	N/A
12/31/2019	14,378	5,889	6,409	7,079	N/A
9/30/2019	14,233	5,396	6,384	7,014	N/A
6/30/2019	14,072	5,294	6,324	7,055	N/A
3/31/2019	13,812	4,667	5,382	6,190	N/A
12/31/2018	13,453	4,431	5,302	6,188	N/A
9/30/2018	13,234	3,187	4,855	5,811	N/A
6/30/2018	12,872	2,968	N/A	5,703	N/A
3/31/2018	12,594	2,964	N/A	5,773	N/A
12/31/2017	12,274	2,539	N/A	4,551	N/A
9/30/2017	11,839	3,486	N/A	4,615	N/A
6/30/2017	11,717	3,293	N/A	3,978	N/A
3/31/2017	11,533	3,480	N/A	3,807	N/A
12/31/2016	11,449	3,703	N/A	4,587	N/A
9/30/2016	11,416	3,885	N/A	4,046	N/A
6/30/2016	11,238	3,818	N/A	3,950	N/A
3/31/2016	10,936	3,695	N/A	3,999	N/A
12/31/2015	10,764	3,547	N/A	3,919	N/A
9/30/2015	10,565	3,599	N/A	3,609	N/A
6/30/2015	10,299	3,490	N/A	3,627	N/A
3/31/2015	10,128	3,277	N/A	3,570	N/A
12/31/2014	9,703	2,935	N/A	2,942	N/A
9/30/2014	9,028	2,509	N/A	2,878	N/A
6/30/2014	8,345	2,139	N/A	2,636	N/A
3/31/2014	7,647	1,916	N/A	2,271	N/A
12/31/2013	6,932	1,862	N/A	2,345	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IDP 'nin tahmini kazanç büyümesi (yıllık 12.4% ) tasarruf oranının ( 1% ) üzerindedir.

Kazançlar ve Piyasa: IDP şirketinin kazançlarının (yıllık 12.4% ) German pazarından (yıllık 20.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: IDP şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: IDP şirketinin gelirinin (yıllık 1.3% ) German pazarından (yıllık 5.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IDP şirketinin gelirinin (yıllık 1.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IDP 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.1 %).

Biogen Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Biogen Inc. Provides Earnings Guidance for the Year 2023

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Third quarter 2024 earnings released: EPS: US$2.67 (vs US$0.47 loss in 3Q 2023)

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023)

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$4.09 (vs US$7.25 in 2Q 2022)

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Insider recently sold €729k worth of stock

First quarter 2023 earnings released: EPS: US$2.69 (vs US$2.07 in 1Q 2022)

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$20.97 (vs US$10.44 in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin